21.3 C
New York
Thursday, June 13, 2024

Biohaven CEO says drug approval is ‘monumental’ for migraine patients

  • Biohaven CEO Vlad Coric told CNBC Tuesday a recent approval of the company's migraine drug will "change the paradigm" of migraine prevention and treatment.
  • Nurtec ODT is the first pill approved for both acute treatment and prevention of migraines, according to Coric.
  • "This is going to change the paradigm in which migraine is treated," he said.

In this article

Related Articles

Latest Articles